We studied the disaggregation of human platelets by tissue-type plasminogen activator (t-PA). When added to a suspension of human platelets induced to aggregate in plasma with adenosine 5'-diphosphate, t-PA promoted disaggregation of platelets over several minutes. Addition of fresh plasma or purified human fibrinogen to disaggregated platelets facilitated (reversible) aggregation and subsequent disaggregation. Aspirin treatment of platelets markedly potentiated the ability of t-PA to induce disaggregation. Disaggregation was inhibited by alpha-2-antiplasmin. Comparative analysis of the rate of proteolysis of plateletbound fibrinogen with that of ambient plasma fibrinogen suggested that fibrinogenolysis of cohesive fibrinogen occurred more rapidly than fibrinogenolysis of ambient fibrinogen. These data demonstrate that t-PA facilitates platelet disaggregation in plasma through kinetically selective proteolysis of cohesive fibrinogen by plasmin, and suggest that thrombolytic mechanisms may serve both to remove platelets from platelet-fibrin thrombi and to disperse circulating platelet aggregates.
Introduction
Tissue-type plasminogen activator (t-PA)' has been intensively studied in recent years as an endogenous biomolecule that is important for initiating fibrinolysis (1) (2) (3) (4) (5) . Plasminogen activation by endogenous t-PA occurs specifically at sites of thrombus formation and fibrin itself enhances this activation (6) . Platelets have also recently been shown to provide a surface that enhances t-PA-induced plasminogen activation (7) . Once generated, plasmin not only catalyzes fibrinolysis but also modifies the platelet surface, inhibiting platelet aggregation (8, 9) . In that thrombi are composed of fibrin and platelets, and that both the fibrin polymer and platelet surface promote t-PA-mediated plasminogen activation, these mechanisms of plasminogen activation serve to confine plasmin production and action to the thrombus.
While modification of platelets by plasmin inhibits aggregation in vitro, the importance of this mechanism in vivo has not been established. Furthermore, since fibrinogen, an alternative substrate for plasmin, is important in maintaining cohesion among platelets induced to aggregate by a variety ofagonists, local promotion of plasmin production at the platelet surface (7, 10) For these reasons, we examined the effect of recombinant t-PA on platelet aggregates produced in vitro in platelet-rich plasma. Our results demonstrate that t-PA promotes platelet disaggregation in plasma and that its does so through proteolysis of cohesive fibrinogen by plasmin. hydrochloride (S-2288) were obtained from KABI Collection and preparation of human platelets. Venous blood was anticoagulated with 13 mM trisodium citrate. Platelet-rich plasma was prepared by centrifugation at 120 g for 10 min at 22°C. The top twothirds of the platelet-rich plasma was removed for aggregation experiments. Platelet counts were determined with a counter equipped with a 50-gm aperture (model ZM; Coulter Electronics Inc., Hialeah, FL). Platelets were kept at 22°C for up to 1 h before use. Platelets were treated with aspirin by incubation for 30 min with 1 mM aspirin at 25°C in platelet-rich plasma. Washed platelets were obtained by centrifuging platelets from platelet-rich plasma at 800 g for 20 min, resuspending the platelets in platelet washing buffer (10 mM triosodium citrate, 0.15 M NaCl, 1 mM ethylenediaminetetraacetate, pH 7.0), centrifuging the platelets at 800 g for 20 min, repeating the suspension in washing buffer and centrifugation, and finally suspending the platelets at 3.0 X 108/ml in modified Tyrode's solution (0.13 M NaCl, 2.7 mM KCI, 12 mM NaHCO3, 0.42 mM NaH2PO4, pH 7.4, 1.0% bovine serum albumin).
Platelet aggregation. Platelets in platelet-rich plasma were typically suspended at a final concentration of 3.0 X 108/ml and aggregated with 1.5 or 11 M ADP, with 0.5 U/ml plasminogen-free bovine thrombin in the presence of 1 mM GPRP, or with 0.12 mg/ml calfskin collagen. Aggregation (16) was monitored at 370C with stirring at 900 rpm using a dual-channel aggregometer (Payton Assoc., Inc., Buffalo, NY).
Platelet disaggregation. Disaggregation of platelets in platelet-rich plasma was induced by addition of t-PA after the aggregation response reached its maximum. Disaggregation was quantitated by measuring either (a) the extent of reduction in light transmittance or (b) the maximal 'Platelet radiojodination. Surface proteins of intact platelets were labeled with 1251 using lactoperoxidase (17, 18 Analytical methods. Plasma fibrinogen was measured by the method of Rampling and Gaffney (22) using 250 U/ml aprotinin to inhibit plasmin immediately before sulphite precipitation. Fibrinogen/fibrin degradation products were determined by the method of Merskey and colleagues (23, 24) . Plasmin activity was measured using the chromogenic substrate S-2251 (25, 26) . Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed according to the method ofLaemmli (27) using 7.5% slab gels. Autoradiograms ofthe dried gels were produced by exposing x-ray film (Eastman Kodak Co., Rochester, NY) to the gels at -20'C. Protein determinations were performed according to the method of Lowry and colleagues (28) .
Results
Disaggregation ofplatelets in platelet-rich plasma by t-PA. The addition of purified t-PA to a suspension of aggregated platelets in platelet-rich plasma produced a rapid decrease in light transmittance indicative of disaggregation ( aggregation and its extent were dependent on the concentration oft-PA as well as the time ofits addition. Higher concentrations oft-PA produced faster rates ofdisaggregation and greater extents of change in light transmittance (Fig. 2 ). In addition, the earlier t-PA was added after ADP, the faster the rate of disaggregation and the greater its extent (Fig. 3) .
Reversibility ofdisaggregation. Once disaggregated, platelets appeared normally discoid in shape by phase-contrast microscopy. Resuspension of these platelets in fresh platelet-poor plasma supported another cycle ofaggregation and disaggregation (Fig. 4) . In this experiment, platelets were induced to aggregate with 11 MM ADP in platelet-rich plasma and 96 ,g/ml t-PA was added 1 min after addition of ADP. The disaggregated platelets were collected by centrifugation at 800 g for 10 min at 250C, resuspended in fresh platelet-poor plasma from the same donor, and subjected to a second cycle ofaggregation and disaggregation using the same concentrations of ADP and t-PA, respectively. Restoration of aggregation was also accomplished by adding 1 mg/ml purified human fibrinogen instead ofplatelet-poor plasma to the disaggregated platelets. Inhibition ofdisaggregation by alpha-2-antiplasmin. Preincubation of platelet-rich plasma with a 1.3-fold molar excess of alpha-2-antiplasmin (15 MAM) over plasmin before addition of APP completely inhibited disaggregation by t-PA, even at t-PA concentrations as high as 96 ug/ml. This concentration ofalpha-2-antiplasmin did not inhibit the activity of t-PA against the chromogenic substrate, S-2288. These data indicate that the proteolytic effect of plasmin, and not the amidolytic effect of t-PA itself, is likely responsible for platelet disaggregation. Potentiation of t-PA-induced disaggregation by aspirin. Treating platelets with aspirin in platelet-rich plasma enhanced markedly the rate of disaggregation over a wide range of t-PA concentrations (Fig. 5) . The EC~v for t-PA decreased by approximately two orders ofmagnitude (to -5 jsg/ml) with platelets treated with aspirin compared with untreated platelets. Importantly, some disaggregation was detected even without aspirin treatment at concentrations of t-PA as low as 5 ug/ml, a pharmacologically achievable concentration (29) , and at concentrations of t-PA as low as 0.5 ,ug/ml with aspirin treatment.
Disaggregation ofwashed platelets by t-PA. To prove further that t-PA had no significant effect on fibrinogen binding to platelets, direct binding experiments were performed using purified radioiodinated fibrinogen. Platelets were either freshly isolated from platelet-rich plasma for use in binding assays, or were obtained from platelet-rich plasma in which they were aggregated with 11 uM ADP then disaggregated with 96 tg/ml t-PA. These disaggregated platelets were obtained 2 min after addition of the t-PA, at which time 250 U/ml aprotinin was added to inhibit further plasmin action. Platelets were then washed twice in platelet washing buffer and fibrinogen binding measured according to standard published methods (19, 21) at 250C in modified Tyrode's buffer, pH 7.4, containing 3.5 mg/ml bovine serum albumin, 5.5 mM glucose, 0.5 mM CaCl2, and 10 uM ADP. The results of these experiments are shown in Scatchard (30) and the data fitted to the best curve according to the method of Rodbard (31).
Lack ofeffect offibrinogen degradation products on platelet aggregates. To assess the effects of fibrinogen degradation products on aggregated platelets, platelet-poor plasma was treated with either (a) 2 U/ml of plasminogen-free bovine thrombin at 25°C for 30 min, which produced 250 1g/ml of fibrinogen degradation products, after which thrombin was inhibited with 5 U/ml hirudin; or (b) 20 ,tg/ml t-PA at 37°C for 20 min, which produced 400 ,g/ml of fibrinogen degradation products, after Collagen-ND"
ND ND * Plasminogen-free bovine thrombin was added to platelet-rich plasma to a final concentration of 0.5 U/ml in the presence of I mM GPRP to inhibit fibrin polymerization. t-PA was added I min after addition of thrombin, by which time the monophasic aggregation response reached a maximum value. Each point represents the mean±standard deviation of three experiments using three different donors, each done in duplicate.
* t-PA was added I min after addition of ADP (I I jM final concentration), by which time the monophasic aggregation response had reached a maximum value. Each point represents the mean±standard deviation of seven experiments using seven different donors, each done in duplicate. i Aggregation was induced with 0.12 mg/ml calf skin collagen and t-PA added 30 s after the monophasic aggregation response reached a maximum value, which was approximately 2 min after collagen addition. 1"ND, No disaggregation detected.
aggregates to plasmin leads to their disaggregation (40) . In contrast, two reports (41, 42) suggest that plasmin induces platelet aggregation. In these two studies, however, washed platelets were used in physiologic buffers rather than platelets in plasma. In the experiments presented here, the effect of human plasmin (produced from ambient plasma plasminogen by the action of recombinant human t-PA) on already formed human platelet aggregates was studied in plasma, making any attempts at direct comparison with earlier work (41, 42) unjustified. The ability of t-PA to induce plasmin-mediated platelet disaggregation was found to be dependent on the concentration of t-PA used, as well as the time of its addition to the aggregated platelets. These observations, in addition to the observation that aspirin treatment of platelets markedly potentiated the disaggregating effects of t-PA, suggest that one possible explanation for this phenomenon is that after the induction of aggregation, platelets become progressively more resistant to disaggregation through one of several possible mechanisms. Either the development of the release reaction (43) , progression to irreversible fibrinogen binding (44, 45) , or both may be important determinants ofthe susceptibility ofplatelets to disaggregation induced by t-PA in plasma. Another explanation for the effect ofaspirin in this system is that aspirin inhibits the use of arachidonate released by plasmins' action on platelets (46) . Further studies will be needed to clarify unequivocally the mechanistic determinants of this phenomenon.
Whether the phenomenon of platelet disaggregation induced by t-PA has any relevance to human pathophysiology or pharmacology has yet to be determined. Clearly, using ADP-induced platelet aggregation in platelet-rich plasma as a model for in vivo platelet thrombus formation, pharmacologically achievable concentrations (29) of t-PA can result in aggregate dispersal.
Whether local concentrations of t-PA secreted by endothelial cells can produce the same effect on small, transiently formed platelet aggregates is not known.
Disaggregation of platelets has been considered by some investigators (47) (48) (49) (50) (51) as an important in vitro measure of the efficacy of antiplatelet agents. The mechanism by which agents that disaggregate platelets act depends upon the specific disaggregant and the agonist used. As Rao and White demonstrated (51), disaggregating ability is selective and depends on the time of addition of disaggregant. In addition, these authors showed that some agents that inhibit aggregation can cause disaggregation, but not all of the agents studied could do so. Finally, they showed that once dissociated, disaggregated platelets were refractory to further addition of agonist, regardless of the agent used.
We have demonstrated that the disaggregation of platelets induced by t-PA in plasma is a direct consequence of plasminogen activation and the action of plasmin on the platelet aggregate. Aggregates produced by the addition of the fibrinogen-dependent agonists, ADP and thrombin, were susceptible to disaggregation by t-PA. Aggregates produced by collagen were resistant to disaggregation by t-PA, probably because platelets aggregate in response to collagen by fibrinogen-independent, as well as fibrinogen-dependent, mechanisms (52), and because platelets adhere to collagen fibrils early in the aggregation process and can undergo secretion before aggregation (53), thereby producing aggregates of different gross morphology containing platelets in different phases of (irreversible) release than with other fibrinogen-dependent agonists.
Disaggregation induced by t-PA was reversible with addition of fresh platelet-poor plasma or of purified human fibrinogen, and disaggregation was accompanied by a kinetically selective loss ofcohesive fibrinogen without a detectable effect ofplasmin under these conditions on platelet fibrinogen receptors (corroborated by the data of Peerschke and colleagues [45] ). These data suggest that t-PA disperses platelet aggregates formed by fibrinogen-dependent agonists through the selective fibrinogenolysis by plasmin of platelet-bound fibrinogen. Whether t-PA has a specific affinity for platelet-bound cohesive fibrinogen similar to that for fibrin, rather than that for unbound fibrinogen, has yet to be determined. In addition, plasmin formed in the platelet aggregate may have effects on other important adhesive proteins, such as thrombospondin and von Willebrand protein, that have yet to be determined; however, the experiments performed in the washed platelet system in which purified fibrinogen restores aggregation argues that in this system fibrinogen alone is the crucial plasmin substrate, the proteolysis of which led to disaggregation.
Miles and Plow (10, 54) have clearly demonstrated that platelets bind plasminogen and that this binding enhances conversion to plasmin by urokinase, streptokinase, and t-PA. Platelet activation by thrombin was found to stimulate plasminogen binding three-to ninefold above that observed with resting platelets. These authors concluded that the binding of plasmin-ogen to the platelet surface localizes and promotes activation of plasminogen and consequent fibnnolysis at an important site of fibnn formation. In the context of these data, our data suggest that plasminogen activation on the platelet surface by t-PA is also important for fibrinogenolysis of platelet-bound, cohesive fibrinogen, and that this mechanism is responsible for the disaggregation of platelets that are maintained as aggregates by fibrinogen. This mechanism may be important in vivo both as a local vascular mechanism for reversing (transient) platelet aggregation as well as a generalized mechanism for promoting the lysis of thrombi containing both platelets and fibrin.
